title: Diagnostic Evaluation as a Biomarker in Patients with ADPKD.
abstract: Recently, newer treatments have been introduced for autosomal dominant polycystic kidney disease (ADPKD) patients. Since cysts grow and renal function declines over a long period of time, the evaluation of treatment effects in ADPKD has been very difficult. Therefore, there has been a great interest to find out the "better" surrogate marker or biomarker which reflects disease progression. Biomarkers in ADPKD should have three clinical implications: (1) They should reflect disease severity, (2) they should distinguish patients with poor versus good prognosis to select those who will benefit better from the treatment, and (3) they should be easy to evaluate short-term outcome after treatment, which will demonstrate hard outcome. Herein, we will discuss currently available surrogate biomarkers including the volume of total kidney and urinary molecular markers.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, The Armed Forces Capital Hospital, Seongnam-si, Gyeonggi-do, South Korea. haynepark798@gmail.com.
authors.forename: Hayne Cho
authors.initials: HC
authors.lastname: Park
authors.affiliation: Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
authors.forename: Curie
authors.initials: C
authors.lastname: Ahn
mesh_terms: D015415:Biomarkers / Q000097:blood / Q000378:metabolism / Q000652:urine; D018450:Disease Progression; D006801:Humans; D016891:Polycystic Kidney, Autosomal Dominant / Q000175:diagnosis* / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D011379:Prognosis; D012306:Risk
chemical_list: D015415:Biomarkers
keywords: Biological markers; Patient selection; Polycystic kidney, autosomal dominant; Prognosis; Treatment outcome